Mon, Dec 29, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Activist hedge fund Breeden Capital poaches Joshua Fenton from Gabelli for Director position

Monday, April 05, 2010
Opalesque Industry Updates - Breeden Capital Management LLC announced Joshua W. Fenton has joined the firm as Senior Managing Director and Director of Research and Trading. Fenton will direct the U.S.- based research team, and serve on the investment committees of the firm’s U.S. and European funds. Fenton comes to Breeden Capital with more than 17 years experience in the investment industry, including nearly ten years with Gabelli Asset Management. Mr. Fenton received a BA in Economics from Yale in 1991, and an MBA from Columbia Business School in 1996.

Richard C. Breeden, Chairman and Chief Executive Officer of Breeden Capital Management, said, “We are excited to be able to add Josh Fenton to our team of investment professionals. Josh brings a superb background in equity investing, together with extensive practical experience and leadership skills. We believe he will add considerably to the talents of our existing investment team and enhance our ability to identify situations where active engagement with portfolio companies can generate significant investment returns. ”

Joshua Fenton said, “I am delighted to join Breeden Capital Management, an outstanding investment fund, and I’m very excited to be working with the very bright and committed team to find ways to generate solid returns for our investors.”

From 2008 through 2009, Mr. Fenton was Director of Global Equity Research at Clay Finlay LLC, where he was a member of the investment committee, oversaw the team of seven analysts and covered global energy, materials and industrials as an analyst himself. Prior to Clay Finlay, he was Director of Research and a co-Portfolio Manager at Gabelli Asset Management, Inc. He joined GAMCO in 2001 as an analyst, became Director of Buy Side Research in 2003 and added the job of co-manager of The Gabelli Global Gold & Natural Resources Trust at the fund’s inception in 2005.

Breeden Capital Management is based in Greenwich, CT. In 2006, the firm launched its “Breeden Partners” fund to invest in the equity securities of companies which the fund believes to be undervalued or underperforming. Through active engagement, the fund seeks to assist portfolio companies in improving performance on a sustainable basis and enhancing long term shareholder value. The firm’s affiliate, Breeden European Capital Management, launched a London-based fund in 2009, whose Director of Research is Ben Barnett, formerly of Fortress Investment Group. In the aggregate, the firms manage more than $1.5 billion in assets. Breeden Capital Management and Breeden European Capital Management were each founded by Richard C. Breeden, who served as Chairman of the U.S. Securities and Exchange Commission from 1989-1993. Mr. Breeden currently serves as non-executive Chairman of the Board of H&R Block, Inc., as well as a director of two additional portfolio companies. He has previously served as Corporate Monitor of WorldCom and MCI, Inc. from 2002-2005, and of the accounting firm KPMG LLP from 2005-2009.

Mr. Fenton replaces Robert Fields, who departed the firm last month.

kn

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Hong Kong-Shanghai stock link fails to live up to expectation so far[more]

    Komfie Manalo, Opalesque Asia: In a report, Reuters said that demand has been subdued with the bulk of activities coming from short-term speculative investors. Las

  2. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  3. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  4. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for

  5. CFTC Revokes Registrations of Illinois Resident Aleks A. Kins and Chicago-based AlphaMetrix, LLC[more]

    Matthias Knab, Opalesque: The U.S. Commodity Futures Trading Commission (CFTC) today announced that it has revoked the registration of Aleks A. Kins of Chicago, Illinois, as an Associated Person and the registrations of AlphaMetrix, LLC (AlphaMetrix), a Delaware limited liability company with its